Personal information

Activities

Works (6)

Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study

BioDrugs
2020 | Journal article
EID:

2-s2.0-85079480889

Contributors: Haridas, V.M.; Katta, R.; Nalawade, A.; Kharkar, S.; Zhdan, V.; Garmish, O.; Lopez-Lazaro, L.; Batra, S.S.; Kankanwadi, S.
Source: Self-asserted source
Olena Garmish via Scopus - Elsevier

Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics‐Naïve Patients with Moderate‐to‐Severe Rheumatoid Arthritis: A Double‐Blind, Randomized, Three‐Arm Study

BioDrugs
2020-01 | Journal article
Source: Self-asserted source
Olena Garmish

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Rheumatology (United Kingdom)
2019 | Journal article
EID:

2-s2.0-85070068083

Contributors: Shim, S.C.; Božić-Majstorović, L.; Berrocal Kasay, A.; El-Khouri, E.C.; Irazoque-Palazuelos, F.; Cons Molina, F.F.; Medina-Rodriguez, F.G.; Miranda, P.; Shesternya, P.; Chavez-Corrales, J. et al.
Source: Self-asserted source
Olena Garmish via Scopus - Elsevier

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Rheumatology
2019-12 | Journal article
Source: Self-asserted source
Olena Garmish

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial

mAbs
2018 | Journal article
EID:

2-s2.0-85050005180

Contributors: Park, W.; Božić-Majstorović, L.; Milakovic, D.; Berrocal Kasay, A.; El-Khouri, E.C.; Irazoque-Palazuelos, F.; Molina, F.F.C.; Shesternya, P.; Miranda, P.; Medina-Rodriguez, F.G. et al.
Source: Self-asserted source
Olena Garmish via Scopus - Elsevier

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.

Mabs
2018-08 | Journal article
Source: Self-asserted source
Olena Garmish